Generative embedding distinguishes recorded two-year depression trajectories
Source check: Source checked. Not independent scientific confirmation.
Finding: In a retrospective reanalysis of 85 NESDA patients, a support-vector classifier using modeled brain connectivity distinguished chronic depression from rapid remission with 79% balanced accuracy in nested cross-validation. The February 2020 journal analysis follows a September 2019 preprint. Small groups, reused data and uncontrolled treatment limit clinical interpretation.
Technology: Linear support vector machine with dynamic-causal-model generative embedding
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- A learned SVM classified later clinical-trajectory labels using posterior connectivity parameters from a conventional generative model; the AI contribution is the discriminative classifier, not an assumption that causal-model terminology proves causation.
- Test and result
- Baseline face-processing fMRI and available two-year follow-up identified 39 rapid-remission, 31 gradual-improvement and 15 chronic-course patients. SVM hyperparameters were optimized using training-only inner five-fold cross-validation inside leave-one-person-out evaluation. Chronic versus rapid-remission classification reached 79% balanced accuracy and ROC AUC .87; gradual versus rapid remission reached 61% but did not survive the stated multiple-comparison correction, and chronic versus gradual improvement was at chance.
- Limitation / still unknown
- This is retrospective prognostic modeling in a selected 85-person cohort, not prospective evaluation of a frozen model. The chronic group comprised only 15 patients; age differed and source-reported age adjustment reduced balanced accuracy to 74%. Treatments and intervening life events were not standardized. An earlier Schmaal analysis used the same source cohort and clinical-trajectory grouping, so this reanalysis is not independent confirmation or first discovery of those trajectories. Source footnotes warn that McNemar comparisons between cross-validated classifiers may be optimistic. The original preprint API dates version1 to September 18, 2019; only its metadata/abstract were available in this review, so journal-specific metrics are not backdated. No individualized-treatment benefit or causal neural mechanism is established.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC7082217/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 21 Nov 2026. Review scope: Original primary computational training, clinical/sample definition, represented Results and bounded Discussion/limitations actually read; earlier primary preprint API metadata/abstract read, not its full tables..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 1/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.